OVERVIEW OF DEVELOPMENT PROGRAM
ROBERT WOLF, M.D., F.A.C.C.
Medicine and Biostatistics and Epidemiology at the University of Pennsylvania School of
not most, patients fail to achieve the ADA recommended target of A1c less than 7.0%.
As shown in this slide, data from recent surveys indicate the majority of
patients with type 2 diabetes in the US, the UK, and in Europe have A1c values above
Chief of the Division of Infectious Diseases at Georgetown University School of
you may have within their respective areas of expertise. I would now like to ask Dr.
Wolf to come forward and to present an overview of our development program. Dr.
a perspective on why it is important to develop novel therapies for type 2 diabetes.
Although several agents are available to treat the hyperglycemia type 2 diabetes, many, if
7.0. Some of the currently available agents have tolerability or safety concerns including
GI intolerability, risk for hypoglycemia, weight gain, and concerns regarding
Dr. Brian Strom, who is Professor of Public Health and Preventive
These individuals will also be available to address specific questions that
Good morning. Prior to describing our development program, I’ll provide
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
Dr. Mark Gorrell, who is Associate Professor at the Centenary Institute
of Cancer Medicine in Cell Biology at the University of Sydney.
Dr. Princy Kumar, who is Professor Of Medicine and Microbiology and